CSPG4 and melanoma: CSPG4 has significant potential as an immunotherapy target, as supported by its expression on a high percentage of melanomas and its prevalence in other cancer histologies and CSCs, as well as, its general lack of expression on normal tissues as demonstrated by immunohistochemistry.